What is Daye?
Daye operates at the intersection of consumer health and medical technology, providing a subscription-based model for organic, sustainable period care products. Beyond its core offering of standard and CBD-infused tampons, the company has distinguished itself through the development of ProViotics, a specialized probiotic solution designed to support vaginal health. The firm is not merely a retail entity but a research-driven organization actively investing in clinical projects to bridge the gender gap in healthcare innovation. By integrating high-quality manufacturing with a commitment to scientific rigor, Daye has carved out a significant niche in the rapidly expanding femtech landscape, appealing to a demographic that prioritizes both environmental sustainability and evidence-based health outcomes.
How much funding has Daye raised?
Daye has raised a total of $11.5M across 1 funding round:
Series A
$11.5M
Series A (2022): $11.5M with participation from MassMutual Ventures, Cross-Border Impact Ventures, and Hambro Perks
Key Investors in Daye
MassMutual Ventures
A multi-stage venture capital firm that invests in financial technology, enterprise software, and digital health companies, providing strategic support to help startups scale effectively.
Cross-Border Impact Ventures
An impact venture capital firm focused on investing in transformative health technology companies that address significant global markets in women, children, and adolescent health.
Hambro Perks
A London-based investment firm that supports high-growth companies through various stages of development, offering both capital and operational expertise to drive international expansion.
What's next for Daye?
With this latest capital injection, Daye is expected to scale its operational footprint and deepen its investment in R&D. The company's strategic roadmap likely includes expanding its diagnostic capabilities and broadening its reach into international markets where demand for premium, health-conscious period care is surging. As the firm continues to challenge traditional medical paradigms, the focus will remain on scaling its ProViotics line and leveraging its research initiatives to influence broader industry standards. Investors are closely watching how Daye will utilize this backing to solidify its market leadership and drive long-term value in the women's health technology sector.
See full Daye company page
